Stepczynska, A., Schanstra, J. P. and Mischak, H. (2016) Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. Bioanalysis, 8(5), pp. 439-455. (doi: 10.4155/bio.16.8) (PMID:26891752)
|
Text
117862.pdf - Accepted Version 1MB |
Abstract
The recent advancements in clinical proteomics enabled identification of biomarker panels for a large range of diseases. A number of CE-MS-identified biomarker panels were verified and implemented in clinical studies. Despite multiple challenges, accumulating evidence supports the value and the need for proteome-based biomarker panels. In this perspective, we provide an overview of clinical studies indicating the added value of CE-MS biomarker panels over traditional diagnostics and monitoring methods. We outline apparent advantages of applying novel proteomic biomarker panels for disease diagnosis, prognosis, staging, drug development and patient management. Facing the plethora of benefits associated with the use of CE-MS biomarker panels, we envision their implementation into the medical practice in the near future
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Mischak, Professor Harald |
Authors: | Stepczynska, A., Schanstra, J. P., and Mischak, H. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
Journal Name: | Bioanalysis |
Publisher: | Future Science Ltd. |
ISSN: | 1757-6180 |
ISSN (Online): | 1757-6199 |
Copyright Holders: | Copyright © 2016 Future Science Ltd. |
First Published: | First published in Bioanalysis 8(5):439-455 |
Publisher Policy: | Reproduced in accordance with the copyright policy of the publisher |
University Staff: Request a correction | Enlighten Editors: Update this record